CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Gilead Sciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Gilead Sciences Inc
333 Lakeside Drive
Phone: (650) 574-3000p:650 574-3000 FOSTER CITY, CA  94404  United States Ticker: GILDGILD
Business Summary
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Anitocabtagene autoleucel, Sacituzumab govitecan-hziy, and Domvanalimab and zimberelimab. Biktarvy is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. It operates in more than 35 countries worldwide.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-YesYes--

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes-YesYes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer Daniel P.O'Day 60 3/1/2019 3/1/2019
Chief Financial Officer Andrew D.Dickinson 55 1/1/2020 6/4/2018
Executive Vice President - Corporate Affairs, General Counsel Deborah H.Telman 60 1/1/2023 8/1/2022
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Gilead Alberta ULC 1021 Hayter Road Edmonton AB Canada
Forty Seven, Inc. 1490 Obrien Dr Menlo Park CA United States
CymaBay Therapeutics Inc SUITE 130, 7999 GATEWAY BLVD NEWARK CA United States
10 additional Subsidiary records available in full report.

Business Names
Business Name
Asegua Therapeutics LLC
CymaBay Canada, Ltd.
CymaBay Ireland, Limited
79 additional Business Names available in full report.

General Information
Number of Employees: 17,600 (As of 12/31/2024)
Outstanding Shares: 1,246,634,469 (As of 3/14/2025)
Shareholders: 1,339
Stock Exchange: NASD
Federal Tax Id: 943047598
Fax Number: (650) 578-9264
Email Address: corporate_communications@gilead.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 8, 2025